 Stephen Frankel
Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Fibrosis | 8 | 2011 | 374 | 1.190 |
Why?
| | Vasculitis | 3 | 2012 | 60 | 0.820 |
Why?
| | Lung Diseases | 5 | 2012 | 722 | 0.750 |
Why?
| | Idiopathic Pulmonary Fibrosis | 6 | 2015 | 628 | 0.640 |
Why?
| | Hospital Mortality | 2 | 2014 | 844 | 0.610 |
Why?
| | Critical Illness | 3 | 2017 | 729 | 0.580 |
Why?
| | Lung Diseases, Interstitial | 9 | 2015 | 592 | 0.520 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 2 | 2012 | 23 | 0.450 |
Why?
| | Churg-Strauss Syndrome | 5 | 2018 | 26 | 0.380 |
Why?
| | Hospitals, Veterans | 1 | 2012 | 257 | 0.360 |
Why?
| | Wounds and Injuries | 2 | 2017 | 714 | 0.360 |
Why?
| | Arteritis | 1 | 2010 | 24 | 0.350 |
Why?
| | Cause of Death | 1 | 2012 | 391 | 0.350 |
Why?
| | Fibroblasts | 5 | 2011 | 939 | 0.330 |
Why?
| | Respiration, Artificial | 2 | 2017 | 594 | 0.320 |
Why?
| | Eosinophilia | 1 | 2011 | 205 | 0.320 |
Why?
| | Respiratory Tract Diseases | 1 | 2010 | 150 | 0.310 |
Why?
| | Intensive Care Units | 1 | 2014 | 718 | 0.310 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2009 | 144 | 0.290 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 2008 | 92 | 0.290 |
Why?
| | Granulomatosis with Polyangiitis | 4 | 2018 | 43 | 0.290 |
Why?
| | Colitis, Ischemic | 1 | 2007 | 6 | 0.280 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2007 | 26 | 0.280 |
Why?
| | Escherichia coli O157 | 1 | 2007 | 30 | 0.280 |
Why?
| | Escherichia coli Infections | 1 | 2007 | 106 | 0.270 |
Why?
| | Venous Thromboembolism | 1 | 2009 | 274 | 0.250 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2004 | 307 | 0.250 |
Why?
| | Exercise Therapy | 1 | 2009 | 414 | 0.240 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2005 | 162 | 0.240 |
Why?
| | Connective Tissue Diseases | 3 | 2013 | 81 | 0.230 |
Why?
| | Apoptosis | 4 | 2011 | 2437 | 0.220 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2005 | 1190 | 0.220 |
Why?
| | Spike Glycoprotein, Coronavirus | 2 | 2022 | 107 | 0.210 |
Why?
| | Antiviral Agents | 2 | 2021 | 704 | 0.210 |
Why?
| | Precancerous Conditions | 1 | 2004 | 161 | 0.210 |
Why?
| | Lung | 6 | 2014 | 3741 | 0.210 |
Why?
| | Adenoma | 1 | 2004 | 214 | 0.200 |
Why?
| | Smoking | 1 | 2009 | 1463 | 0.190 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2022 | 759 | 0.190 |
Why?
| | Humans | 34 | 2022 | 128524 | 0.180 |
Why?
| | Hypertension, Pulmonary | 2 | 2009 | 1735 | 0.180 |
Why?
| | Mycophenolic Acid | 2 | 2013 | 92 | 0.160 |
Why?
| | Diagnosis, Differential | 4 | 2011 | 1416 | 0.160 |
Why?
| | Biomarkers | 1 | 2010 | 3881 | 0.160 |
Why?
| | fas Receptor | 2 | 2011 | 95 | 0.150 |
Why?
| | Ganciclovir | 1 | 2017 | 51 | 0.140 |
Why?
| | Interferon-gamma | 2 | 2013 | 761 | 0.130 |
Why?
| | Cytomegalovirus | 1 | 2017 | 153 | 0.130 |
Why?
| | Aged | 13 | 2017 | 21971 | 0.130 |
Why?
| | Middle Aged | 14 | 2018 | 30893 | 0.130 |
Why?
| | Mutation | 3 | 2022 | 3692 | 0.130 |
Why?
| | Cytomegalovirus Infections | 1 | 2017 | 187 | 0.120 |
Why?
| | Tomography, X-Ray Computed | 5 | 2015 | 2521 | 0.120 |
Why?
| | Survival Rate | 4 | 2015 | 1872 | 0.120 |
Why?
| | Male | 17 | 2017 | 62883 | 0.110 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 87 | 0.110 |
Why?
| | Interleukin-6 | 1 | 2017 | 716 | 0.110 |
Why?
| | Immunosuppressive Agents | 2 | 2018 | 686 | 0.110 |
Why?
| | Physical Therapy Modalities | 1 | 2016 | 290 | 0.100 |
Why?
| | Female | 16 | 2018 | 68127 | 0.100 |
Why?
| | Hypereosinophilic Syndrome | 1 | 2011 | 10 | 0.100 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2011 | 11 | 0.100 |
Why?
| | Lung Neoplasms | 1 | 2004 | 2323 | 0.100 |
Why?
| | Pulmonary Alveoli | 2 | 2011 | 366 | 0.090 |
Why?
| | Pulmonary Eosinophilia | 1 | 2011 | 26 | 0.090 |
Why?
| | Immunologic Factors | 1 | 2013 | 229 | 0.090 |
Why?
| | Respiratory Insufficiency | 2 | 2017 | 311 | 0.090 |
Why?
| | Sepsis | 1 | 2017 | 556 | 0.090 |
Why?
| | Rheumatic Diseases | 1 | 2011 | 69 | 0.090 |
Why?
| | Bronchoscopy | 1 | 2011 | 208 | 0.090 |
Why?
| | Biopsy | 2 | 2014 | 1085 | 0.080 |
Why?
| | Antibodies, Neutralizing | 2 | 2022 | 255 | 0.080 |
Why?
| | Follow-Up Studies | 4 | 2017 | 4898 | 0.080 |
Why?
| | Antibodies, Antinuclear | 1 | 2009 | 65 | 0.080 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2009 | 21 | 0.080 |
Why?
| | Amino Acyl-tRNA Synthetases | 1 | 2009 | 30 | 0.080 |
Why?
| | Idiopathic Interstitial Pneumonias | 1 | 2009 | 49 | 0.080 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2015 | 73 | 0.080 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2013 | 377 | 0.070 |
Why?
| | Up-Regulation | 1 | 2011 | 826 | 0.070 |
Why?
| | Disease Progression | 2 | 2015 | 2603 | 0.070 |
Why?
| | Fatal Outcome | 1 | 2008 | 301 | 0.070 |
Why?
| | Respiratory Tract Infections | 1 | 2011 | 370 | 0.070 |
Why?
| | Acute Lung Injury | 1 | 2010 | 264 | 0.070 |
Why?
| | Survival Analysis | 1 | 2010 | 1265 | 0.070 |
Why?
| | Pericardium | 1 | 2007 | 54 | 0.070 |
Why?
| | Prognosis | 3 | 2009 | 3780 | 0.070 |
Why?
| | Biopsy, Needle | 1 | 2007 | 189 | 0.070 |
Why?
| | Cells, Cultured | 4 | 2011 | 4008 | 0.070 |
Why?
| | Comorbidity | 1 | 2011 | 1540 | 0.070 |
Why?
| | Anastomosis, Surgical | 1 | 2007 | 150 | 0.070 |
Why?
| | Arthritis, Rheumatoid | 1 | 2015 | 1108 | 0.070 |
Why?
| | Colectomy | 1 | 2007 | 94 | 0.070 |
Why?
| | Cysts | 1 | 2007 | 108 | 0.070 |
Why?
| | Rare Diseases | 1 | 2007 | 103 | 0.070 |
Why?
| | Scleroderma, Systemic | 1 | 2007 | 104 | 0.060 |
Why?
| | Fas-Associated Death Domain Protein | 1 | 2005 | 9 | 0.060 |
Why?
| | Abdominal Pain | 1 | 2007 | 146 | 0.060 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2006 | 34 | 0.060 |
Why?
| | Lung Transplantation | 1 | 2008 | 275 | 0.060 |
Why?
| | Autoantibodies | 1 | 2013 | 1463 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 968 | 0.060 |
Why?
| | Respiratory Function Tests | 3 | 2014 | 582 | 0.060 |
Why?
| | Wound Healing | 1 | 2008 | 310 | 0.060 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2005 | 82 | 0.060 |
Why?
| | Pleura | 1 | 2004 | 21 | 0.060 |
Why?
| | Heart Rate | 1 | 2009 | 804 | 0.060 |
Why?
| | Colonoscopy | 1 | 2007 | 233 | 0.060 |
Why?
| | Protein Binding | 2 | 2021 | 2097 | 0.060 |
Why?
| | Retrospective Studies | 4 | 2010 | 14460 | 0.060 |
Why?
| | Proline | 1 | 2005 | 78 | 0.060 |
Why?
| | Walking | 1 | 2009 | 494 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 179 | 0.060 |
Why?
| | Hyperplasia | 1 | 2004 | 170 | 0.060 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2004 | 120 | 0.060 |
Why?
| | Vital Capacity | 2 | 2015 | 289 | 0.060 |
Why?
| | Echocardiography | 1 | 2007 | 625 | 0.060 |
Why?
| | Gene Expression | 2 | 2009 | 1462 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2004 | 213 | 0.050 |
Why?
| | Bleomycin | 1 | 2004 | 240 | 0.050 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 343 | 0.050 |
Why?
| | Cohort Studies | 2 | 2015 | 5369 | 0.050 |
Why?
| | Polyarteritis Nodosa | 1 | 2002 | 5 | 0.050 |
Why?
| | Immunohistochemistry | 1 | 2007 | 1669 | 0.050 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2005 | 391 | 0.050 |
Why?
| | Takayasu Arteritis | 1 | 2002 | 15 | 0.050 |
Why?
| | Incidence | 1 | 2009 | 2619 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 2 | 2015 | 857 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2017 | 10163 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2007 | 2736 | 0.050 |
Why?
| | Intestinal Mucosa | 1 | 2007 | 575 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 126 | 0.050 |
Why?
| | Radiography | 1 | 2004 | 864 | 0.050 |
Why?
| | Age Factors | 1 | 2009 | 3117 | 0.050 |
Why?
| | Fibrosis | 1 | 2004 | 522 | 0.050 |
Why?
| | Immunity, Humoral | 1 | 2022 | 117 | 0.050 |
Why?
| | Longitudinal Studies | 3 | 2014 | 2697 | 0.050 |
Why?
| | Antigen-Antibody Reactions | 1 | 2021 | 51 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2015 | 1494 | 0.050 |
Why?
| | Macrophages, Alveolar | 1 | 2004 | 379 | 0.050 |
Why?
| | Aged, 80 and over | 2 | 2010 | 7040 | 0.050 |
Why?
| | Surface Plasmon Resonance | 1 | 2021 | 88 | 0.040 |
Why?
| | Receptors, Virus | 1 | 2021 | 83 | 0.040 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 109 | 0.040 |
Why?
| | Forced Expiratory Volume | 2 | 2015 | 509 | 0.040 |
Why?
| | Ligands | 1 | 2022 | 614 | 0.040 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 137 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2004 | 2069 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2015 | 1208 | 0.040 |
Why?
| | Pneumonia | 1 | 2004 | 599 | 0.040 |
Why?
| | Amino Acids | 1 | 2022 | 474 | 0.040 |
Why?
| | Cell Line | 3 | 2011 | 2731 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 348 | 0.040 |
Why?
| | Kinetics | 1 | 2021 | 1616 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2017 | 70 | 0.040 |
Why?
| | Binding Sites | 1 | 2021 | 1239 | 0.040 |
Why?
| | Virus Activation | 1 | 2017 | 81 | 0.030 |
Why?
| | Mice | 4 | 2011 | 16579 | 0.030 |
Why?
| | Risk Factors | 1 | 2009 | 9727 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2018 | 469 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2022 | 2674 | 0.030 |
Why?
| | Mice, Inbred C3H | 2 | 2005 | 274 | 0.030 |
Why?
| | Adult | 4 | 2017 | 35315 | 0.030 |
Why?
| | Rituximab | 1 | 2013 | 163 | 0.030 |
Why?
| | Predictive Value of Tests | 2 | 2009 | 1936 | 0.030 |
Why?
| | Patient Dropouts | 1 | 2013 | 65 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2017 | 1860 | 0.030 |
Why?
| | Microscopic Polyangiitis | 1 | 2012 | 13 | 0.030 |
Why?
| | Animals | 4 | 2011 | 34501 | 0.020 |
Why?
| | Length of Stay | 1 | 2017 | 1121 | 0.020 |
Why?
| | Necrosis | 1 | 2012 | 231 | 0.020 |
Why?
| | Fas Ligand Protein | 1 | 2011 | 59 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2011 | 140 | 0.020 |
Why?
| | Alanine-tRNA Ligase | 1 | 2009 | 4 | 0.020 |
Why?
| | Threonine-tRNA Ligase | 1 | 2009 | 4 | 0.020 |
Why?
| | Elastin | 1 | 2009 | 78 | 0.020 |
Why?
| | Myoblasts | 1 | 2009 | 80 | 0.020 |
Why?
| | Oximetry | 1 | 2009 | 86 | 0.020 |
Why?
| | Syndrome | 1 | 2009 | 335 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 512 | 0.020 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2007 | 66 | 0.020 |
Why?
| | Transfection | 1 | 2009 | 895 | 0.020 |
Why?
| | Collagen | 1 | 2009 | 429 | 0.020 |
Why?
| | Exercise Test | 1 | 2009 | 615 | 0.020 |
Why?
| | Medical Records | 1 | 2006 | 169 | 0.020 |
Why?
| | Consensus Sequence | 1 | 2005 | 72 | 0.020 |
Why?
| | Asparagine | 1 | 2005 | 28 | 0.020 |
Why?
| | NF-kappa B | 1 | 2009 | 651 | 0.010 |
Why?
| | COS Cells | 1 | 2005 | 184 | 0.010 |
Why?
| | Sequence Deletion | 1 | 2005 | 179 | 0.010 |
Why?
| | Serine | 1 | 2005 | 136 | 0.010 |
Why?
| | Cytoplasm | 1 | 2005 | 258 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2011 | 2752 | 0.010 |
Why?
| | Growth Substances | 1 | 2004 | 151 | 0.010 |
Why?
| | Culture Media, Conditioned | 1 | 2004 | 108 | 0.010 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2005 | 358 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2011 | 1687 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2004 | 148 | 0.010 |
Why?
| | Logistic Models | 1 | 2009 | 1975 | 0.010 |
Why?
| | Th2 Cells | 1 | 2004 | 167 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2009 | 1036 | 0.010 |
Why?
| | Cell Communication | 1 | 2004 | 293 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 836 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2004 | 421 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2009 | 2335 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2009 | 3326 | 0.010 |
Why?
| | Inflammation | 1 | 2012 | 2664 | 0.010 |
Why?
| | Cell Membrane | 1 | 2005 | 722 | 0.010 |
Why?
| | Cell Survival | 1 | 2004 | 1077 | 0.010 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 634 | 0.010 |
Why?
| | Phosphorylation | 1 | 2005 | 1681 | 0.010 |
Why?
| | Prospective Studies | 1 | 2011 | 7043 | 0.010 |
Why?
| | Young Adult | 1 | 2009 | 12320 | 0.010 |
Why?
| | Adolescent | 1 | 2009 | 20213 | 0.010 |
Why?
|
|
Frankel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|